-
公开(公告)号:EP4410292A1
公开(公告)日:2024-08-07
申请号:EP22876159.9
申请日:2022-09-27
发明人: TACHIBANA Yuki , UEHARA Shota , UNOH Yuto , NAKAHARA Kenji , TAODA Yoshiyuki , KASAMATSU Koji , YAMATSU Yukiko , ANDO Shigeru , FUKAO Keita , NOBORI Haruaki , KURODA Takayuki , TOBA Shinsuke , UEMURA Kentaro , MARUYAMA Yuki , SASAKI Michihito , SAWA Hirofumi
IPC分类号: A61K31/5355 , A61K31/53 , A61K31/5377 , A61P31/12 , A61P31/14 , A61P43/00
CPC分类号: A61P31/12 , A61P43/00 , A61K31/5355 , A61K31/5377 , A61K31/53 , A61P31/14
摘要: The present invention provides a pharmaceutical composition comprising a compound exhibiting coronavirus proliferation inhibitory activity.
A pharmaceutical composition comprising a compound represented by the formula: wherein Y is N; R1 is substituted or unsubstituted aromatic heterocyclyl; R2 is substituted or unsubstituted 6-membered aromatic carbocyclyl; R3 is substituted or unsubstituted aromatic heterocyclyl; -X- is -NH-; m is 0 or 1; R5a is a hydrogen atom; R5b is a hydrogen atom; n is 1; R4a is a hydrogen atom; and R4b is a hydrogen atom, or a pharmaceutically acceptable salt thereof.-
公开(公告)号:EP4317439A1
公开(公告)日:2024-02-07
申请号:EP22781256.7
申请日:2022-03-31
发明人: YOSHIDA, Tetsuya , YOSHIKAWA, Mai , HARUNA, Miya , NAGIRA, Morio , TAKAHASHI, Koji , HAYASHIDA, Marina , MIWA, Hiroto , SONODA, Yudai , OHKURA, Naganari , SAKAGUCHI, Shimon , WADA, Hisashi
IPC分类号: C12N15/62 , A61K35/17 , A61P35/00 , C07K14/725 , C07K16/28 , C07K19/00 , C12N5/10 , C12N15/12 , C12N15/13 , C12N15/63
摘要: The chimeric antigen receptor that recognizes CCR8 as an antigen of the present invention has cytotoxic activity against CCR8-expressing cells by being expressed in effector cells.
-
公开(公告)号:EP4289814A1
公开(公告)日:2023-12-13
申请号:EP22749755.9
申请日:2022-02-02
申请人: Shionogi & Co., Ltd
发明人: KUGIMIYA Akira , NAKAMURA Jun , KURODA Norikazu , TANINO Tetsuya , HAYATA Atsushi , MORITA Ippei , KITAHATA Shun
IPC分类号: C07C217/08
摘要: The present invention provides novel cationic lipids having excellent encapsulation and delivery stability of nucleic acid medicines. Provided is a compound represented by Formula (I) or a pharmacologically acceptable salt thereof. In the Formula (I), R 1 is a substituted or unsubstituted formula: - (CH 2 ) a -L 1 -(CH 2 ) b -CH 3 ; R 2 is a substituted or unsubstituted C5-C20 alkyl group or a substituted or unsubstituted formula: -(CH 2 ) c -L 2 -(CH 2 ) d -CH 3 ; L 1 and L 2 are each independently -C(=O)O-, -OC(=O)-, or -OC(=O)O-; a, b, c, and d are each independently an integer of at least 1, and the total of a and b and the total of c and d are each an integer of 5 to 25; R 3 to R 7 are each independently a hydrogen atom, a substituted or unsubstituted C 1 -C 6 alkyl group, or the like; R 8 , R 9 , and R 10 are each a hydrogen atom; the constituent atoms in the Formula (I) may form a ring; Z is -OC(=O)-, -C(=O)O-, -OC(=O)O-, or the like; and X is O or S.
-
公开(公告)号:EP4257137A2
公开(公告)日:2023-10-11
申请号:EP23192706.2
申请日:2019-05-30
申请人: Shionogi & Co., Ltd
发明人: TAODA, Yoshiyuki , UNOH, Yuto
IPC分类号: A61K31/55
摘要: The present invention provides a compound represented by Formula (I):
wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R 1 is halogen or the like; R 2a and R 2b are each independently hydrogen or the like; R 3 is substituted or unsubstituted alkyl or the like; R 4 is hydrogen or the like; and n is an integer of 1 to 3.-
公开(公告)号:EP4194459A1
公开(公告)日:2023-06-14
申请号:EP22206730.8
申请日:2017-06-19
申请人: Shionogi & Co., Ltd
IPC分类号: C07D498/14 , A61P31/16 , A61K31/5383
摘要: The present invention provides a process for preparing a compound of the formula (II):
wherein R 2 is unsubstituted alkyl,
characterized by reacting a compound of the formula (I):
wherein R 1 is hydrogen or a protecting group other than unsubstituted alkyl,
with a compound of the formula: R 2 -OH, wherein R 2 is as defined above, in the presence of a sodium salt and/or a magnesium salt.-
6.
公开(公告)号:EP4028130A1
公开(公告)日:2022-07-20
申请号:EP20863977.3
申请日:2020-09-10
IPC分类号: A61P31/04 , C07D471/04 , A61K31/437 , A61K31/4545 , A61K31/496 , A61K31/498 , A61K31/499 , A61K31/4995
-
公开(公告)号:EP3976031A1
公开(公告)日:2022-04-06
申请号:EP20814041.8
申请日:2020-05-28
发明人: NISHIGUCHI, Kenzo , MIYAGAWA, Satoshi , CLAYPOOL, William D. , MILLER, Marvin J. , MORASKI, Garrett C. , SCHOREY, Jeffrey S.
IPC分类号: A61K31/4353 , A61K31/437 , A61P31/00 , C07D221/00 , C07D471/02 , C07D471/04
-
公开(公告)号:EP3957627A1
公开(公告)日:2022-02-23
申请号:EP21196697.3
申请日:2016-04-22
申请人: Shionogi & Co., Ltd
发明人: Tanaka, Satoru , Ogawa, Tomoyuki , Kai, Hiroyuki , Ogata, Yuki , Hirai, Keiichiro , Kurose, Noriyuki , Fujii, Yasuhiko
IPC分类号: C07D213/69 , A61K31/4412 , A61K31/505 , A61K31/506 , A61K31/53 , A61K31/5377 , A61P1/02 , A61P1/04 , A61P1/16 , A61P1/18 , A61P3/10 , A61P9/10 , A61P11/00 , A61P11/06 , A61P11/08 , A61P13/00 , A61P13/08 , A61P13/10 , A61P13/12 , A61P17/02
摘要: A compound for use as P2X7 antagonist represented by Formula (I):
wherein
or the like
Y 1 is O or the like; Z 1 is C(R 4 ) or N; Z 2a is C(R 5a ) or the like; Z 3a is C(R 6 ) or the like;
R 4 , R 5a and R 6 are each independently a hydrogen atom or the like; R 1 is substituted or unsubstituted aromatic carbocyclyl or the like; R 2a , R 2b , R 2c and R 2d are each independently a hydrogen atom or the like; X is N(R 7a ) or the like; R 7a is a hydrogen atom or the like; R 3 is
or the like
Ring B is a 6-membered aromatic carbocycle or the like; R 9a and R 10a are each independently halogen or the like; n is an integer from 1 to 5; m is an integer from 0 to 4; and p1 is an integer from 0 to 3,
or a pharmaceutically acceptable salt thereof.-
公开(公告)号:EP3954989A1
公开(公告)日:2022-02-16
申请号:EP20787320.9
申请日:2020-04-07
申请人: Shionogi & Co., Ltd
IPC分类号: G01N33/15
摘要: When the mesh is placed under the bottom of a blade and over the bottom of a vessel in the dissolution test assembly equipped with either a vessel specified in the dissolution test method of the Japanese Pharmacopoeia, the United States Pharmacopoeia or the European Pharmacopoeia or a vessel used for the dissolution test, and a paddle formed from a blade and a shaft, and the suspensions and the solid dosage forms are added to or placed at the said mesh, a drug dissolves from the said dosage forms and the dissolution ratio variation between the said multiple same dosage forms can be small.
-
公开(公告)号:EP3858860A1
公开(公告)日:2021-08-04
申请号:EP20216033.9
申请日:2018-03-28
发明人: YOSHIDA, Tetsuya , KIDANI, Yujiro , MATSUMOTO, Mitsunobu , KANAZAWA, Takayuki , SHINONOME, Satomi , HOJO, Kanji , OHKURA, Naganari , SAKAGUCHI, Shimon , TANAKA, Atsushi , WADA, Hisashi , KAWASHIMA, Atsunari , NONOMURA, Norio
IPC分类号: C07K16/28 , A61K39/395 , A61P35/00
摘要: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.
-
-
-
-
-
-
-
-
-